We are live on ! Find out more
ABEO icon

Abeona Therapeutics

75 hedge funds and large institutions have $335M invested in Abeona Therapeutics in 2017 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

544% more call options, than puts

Call options by funds: $27.1M | Put options by funds: $4.21M

239% more capital invested

Capital invested by funds: $98.6M → $335M (+$236M)

93% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 15

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

7% more funds holding

Funds holding: 7075 (+5)

0.42% more ownership

Funds ownership: 1.53%1.95% (+0.42%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
75
Holders Change
+5
Holders Change %
+7.14%
% of All Funds
1.87%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
29
Reduced
15
Closed
11
Calls
$27.1M
Puts
$4.21M
Net Calls
+$22.9M
Net Calls Change
+$19M

ABEO Hedge Fund Activity: Q3 2017 in Review

75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2017, worth a combined $335M — up 239% from $98.6M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ABEO positions and 11 closed out — a net gain of 5 holders — while 29 added to existing stakes and 15 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $24.1M. The largest seller was Soros Fund Management, exiting entirely with an estimated $5.74M sold.

  • 75 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2017, up from 70 in Q2 2017.
  • Funds reported $335M of Abeona Therapeutics stock for Q3 2017, up 239% quarter-over-quarter.
  • 16 funds opened new Abeona Therapeutics positions in Q3 2017 and 11 closed out, a net change of +5 holders.
  • The largest Abeona Therapeutics buyer in Q3 2017 was Viking Global Investors, an estimated $24.1M added.
  • The largest Abeona Therapeutics seller in Q3 2017 was Soros Fund Management, an estimated $5.74M sold.

Based on aggregated 13F filings for Q3 2017.